公开(公告)号：US11912772B2

公开(公告)日：2024-02-27

申请号：US17260077

申请日：2019-07-12

申请人： University of Hawaii

发明人： Lishomwa C. Ndhlovu ,  Toshiro Niki

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/47

CPC分类号： C07K16/2851 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/505

摘要： An antibody targeting Galectin-9 is provided as are methods of using the same treatment of chronic immune conditions such as infections, inflammatory diseases and cancer, in particular malignant mesothelioma.

公开(公告)号：US20180153901A1

公开(公告)日：2018-06-07

申请号：US15558178

申请日：2016-03-10

申请人： Blood Systems, Inc. ,  University of Hawaii ,  GalPharma Co., Ltd.

发明人： Satish K. Pillai ,  Mohamed Abdel-Mohsen ,  Leonard Chavez ,  Lishomwa Ndhlovu ,  Ravi Tandon ,  Toshiro Niki ,  Misuomi Harashima

IPC分类号： A61K31/551 ,  A61K38/17 ,  A61K45/06

CPC分类号： A61K31/551 ,  A61K38/1732 ,  A61K45/06 ,  A61P31/12 ,  C12N2740/16063 ,  A61K2300/00

摘要： The present invention relates to the seminal discovery of methods of using recombinant galectin proteins to reverse HIV latency. Specifically, the present invention relates to the use of recombinant galectin-9 (rGal-9) to reactivate latent HIV, wherein the HIV is hypermutated rendering the virus replication incompetent. Further, rGal-9 induces the expression of APOBEC3 cytidine deaminases and NFkB pathway components and decreases histone deacetylase (HDAC) expression.